Cindy J Bednasz1, Charles S Venuto, Qing Ma, Eric S Daar, Paul E Sax, Margaret A Fischl, Ann C Collier, Kimberly Y Smith, Camlin Tierney, Yang Yang, Gregory E Wilding, Gene D Morse. 1. *AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York; †Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York; ‡Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and the University of California, Los Angeles, California; §Division of Infectious Diseases and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; ¶University of Miami School of Medicine, Miami, Florida; ‖University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington; **ViiV Healthcare, Research Triangle Park, North Carolina; ††Statistical Data Analysis Center, Harvard T. H. Chan School of Public Health, Boston, Massachusetts; and ‡‡Department of Biostatistics, University at Buffalo, Buffalo, New York.
Abstract
BACKGROUND: Efavirenz is currently suggested as an alternative to recommended antiretroviral (ARV) regimens by the Department of Health and Human Services for the treatment of HIV-1 in ARV-naive patients. A mid-dosing interval therapeutic range between 1000 and 4000 ng/mL for efavirenz has been proposed in the literature, with patients more likely to experience virologic failure below this range and adverse effects above. The current study reports an analysis of virologic outcome between those above, below, or within the reported efavirenz therapeutic range (1000-4000 ng/mL) and within subgroups. METHODS: This analysis examined efavirenz plasma concentrations obtained from participants enrolled in AIDS Clinical Trials Group Study A5202. This investigation divided subjects into those who experienced virologic failure and those who did not. These subjects were further separated to investigate those who had "high," "within," or "low" plasma concentrations, based on the therapeutic range. The association between virologic failure and plasma concentration was statistically examined in addition to the variables: race/ethnicity, sex, assigned nucleos(t)ide reverse transcriptase inhibitor backbone, age at study entry, history of intravenous drug use, weight, and screening HIV-1 RNA stratification level. RESULTS: In univariate analyses, a statistically significant difference was found when comparing the efavirenz concentration groups, (22 failures among the "low" concentration group [19%], 65 failures among the "within" concentration group [12%], and 11 failures among the "high" concentration group [9%]) when evaluating virologic failure as an outcome (P = 0.04). In addition, the proportion of participants with virologic failure differed across race/ethnicity groups (P = 0.03) with black non-Hispanic participants observed to have the highest rate (17%). Efavirenz concentration group, race/ethnicity, age, weight, and the interaction between efavirenz concentration group and weight were found to be significantly associated with virologic failure in multivariable logistic regression analysis. CONCLUSIONS: The proposed efavirenz therapeutic range, combined with the impact of a patient's weight, is associated with virologic failure in HIV-infected ARV-naive individuals in the United States. Additional analysis is recommended to determine the most appropriate concentration value that defines the lower limit of the efavirenz therapeutic range.
BACKGROUND:Efavirenz is currently suggested as an alternative to recommended antiretroviral (ARV) regimens by the Department of Health and Human Services for the treatment of HIV-1 in ARV-naivepatients. A mid-dosing interval therapeutic range between 1000 and 4000 ng/mL for efavirenz has been proposed in the literature, with patients more likely to experience virologic failure below this range and adverse effects above. The current study reports an analysis of virologic outcome between those above, below, or within the reported efavirenz therapeutic range (1000-4000 ng/mL) and within subgroups. METHODS: This analysis examined efavirenz plasma concentrations obtained from participants enrolled in AIDS Clinical Trials Group Study A5202. This investigation divided subjects into those who experienced virologic failure and those who did not. These subjects were further separated to investigate those who had "high," "within," or "low" plasma concentrations, based on the therapeutic range. The association between virologic failure and plasma concentration was statistically examined in addition to the variables: race/ethnicity, sex, assigned nucleos(t)ide reverse transcriptase inhibitor backbone, age at study entry, history of intravenous drug use, weight, and screening HIV-1 RNA stratification level. RESULTS: In univariate analyses, a statistically significant difference was found when comparing the efavirenz concentration groups, (22 failures among the "low" concentration group [19%], 65 failures among the "within" concentration group [12%], and 11 failures among the "high" concentration group [9%]) when evaluating virologic failure as an outcome (P = 0.04). In addition, the proportion of participants with virologic failure differed across race/ethnicity groups (P = 0.03) with black non-Hispanic participants observed to have the highest rate (17%). Efavirenz concentration group, race/ethnicity, age, weight, and the interaction between efavirenz concentration group and weight were found to be significantly associated with virologic failure in multivariable logistic regression analysis. CONCLUSIONS: The proposed efavirenz therapeutic range, combined with the impact of a patient's weight, is associated with virologic failure in HIV-infected ARV-naive individuals in the United States. Additional analysis is recommended to determine the most appropriate concentration value that defines the lower limit of the efavirenz therapeutic range.
Authors: Kimberly Y Smith; Camlin Tierney; Katie Mollan; Charles S Venuto; Chakra Budhathoki; Qing Ma; Gene D Morse; Paul Sax; David Katzenstein; Catherine Godfrey; Margaret Fischl; Eric S Daar; Ann C Collier Journal: Clin Infect Dis Date: 2013-11-18 Impact factor: 9.079
Authors: Emily R Holzinger; Benjamin Grady; Marylyn D Ritchie; Heather J Ribaudo; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David B Clifford; Eric S Daar; Paul McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2012-12 Impact factor: 2.089
Authors: L Dickinson; J Amin; L Else; M Boffito; D Egan; A Owen; S Khoo; D Back; C Orrell; A Clarke; M Losso; P Phanuphak; D Carey; D A Cooper; S Emery; R Puls Journal: Clin Pharmacol Ther Date: 2015-07-14 Impact factor: 6.875
Authors: Marta Bull; Caroline Mitchell; Jaime Soria; Sheila Styrchak; Corey Williams; Joan Dragavon; Kevin J Ryan; Edward Acosta; Frankline Onchiri; Robert W Coombs; Alberto La Rosa; Eduardo Ticona; Lisa M Frenkel Journal: J Infect Dis Date: 2020-08-04 Impact factor: 5.226
Authors: Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Edward P Acosta; Donald E Mager; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: Ahmad Haeri Mazanderani; Tanya Y Murray; Gayle G Sherman; Tracy Snyman; Jaya George; Theunis Avenant; Ameena E Goga; Michael S Pepper; Nicolette du Plessis Journal: J Int AIDS Soc Date: 2019-06 Impact factor: 5.396